(CAMBRIDGE, UK AND TORONTO, CANADA) September 06, 2018 – Breakthrough innovation specialist Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu™ micro-ultrasound platform, as the two companies work to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise.
Prostate cancer is the second most common cause of cancer death in men in both the USA and the UK. There is an urgent need for improved accuracy in the detection and diagnosis of aggressive prostate cancers. The current standard-of-care ultrasound, which guides prostatic needle biopsies that help to diagnose prostate cancer, yields a 30% false negative rate as the resolution of the ultrasound systems is insufficient to differentiate suspicious regions. As such, the prostate biopsies are usually delivered in a systematic, “blind” pattern .
The ExactVu™ micro-ultrasound platform is a significant new imaging tool to allow urologists to harness “micro” ultrasound’s near microscopic resolution in order to visualize suspicious regions and actually target their biopsies to those regions. Operating at 29 MHz, the micro-ultrasound provides a 300% improvement in resolution over conventional ultrasound.
Cambridge Consultants aims to harness higher resolution micro-ultrasound images from the ExactVu™ platform, in combination with decades of medical technology expertise and cutting-edge machine learning techniques, to provide new information to urologists to help them to improve their targeting of prostate biopsies. In recent years Cambridge Consultants has been at the forefront of advances in machine learning and deep learning, applying this transformative technology to a wide range of industries and disciplines.
With their AI tools able to interrogate the full ultrasound data set correlated to pathology, the analysis should deliver improved accuracy and better characterization of suspicious regions. The machine learning approach being applied is faster and less computationally intensive than traditional statistical approaches and may ultimately form the backbone of a commercially-viable software application. Early results from proof of concept testing show significant promise, even with relatively limited data sets.
Shweta Gupta, Head of Urology and Women’s Health at Cambridge Consultants commented: “The need for effective management of prostate cancer is as pressing as ever. We are proud to have the opportunity to try and improve the detection pathway and excited by the opportunity to apply deep learning to this significant clinical problem.”
The current work on prostate cancer is the latest output from Cambridge Consultants’ Digital Greenhouse – a unique experimental environment where data scientists and engineers explore and develop cutting edge machine learning and deep learning techniques. Recent work has focused on applying deep learning in areas where massive datasets are unavailable - in this case data was available on hundreds of patients - aiming to ensure that deep learning is potent beyond the huge online datasets that have powered advances to date.
Cambridge Consultants （剑桥顾问公司）开发突破性产品，产生和授权知识产权，并为全球的客户提供商业资讯，解决与技术相关的关键问题。60多年来，公司一直致力于帮助客户转化商业机会，包括推出市场领先的产品，进入新市场，引入新技术扩大现有市场。公司拥有超过900名员工，包括工程师、科学家、数学家和设计师，遍布于英国剑桥、美国波士顿、东京和新加坡办事处，为医疗和生命科学、工业和能源、消费和零售以及通讯和基础设施等多个行业提供解决方案。欲了解更多信息，请访问: www.cambridgeconsultants.com。
Cambridge Consultants是 Capgemini Invent （凯捷集团的创新、咨询和转型品牌）的子公司。Capgemini Invent帮助管理者设想和构建他们组织的未来。公司在全球设有30多个办事处和25个创意工作室，是一支拥有7000多名员工的强大团队，将战略、技术、数据科学和创意设计与深厚的行业专业知识和洞察力相结合，开发新的数字解决方案和未来的商业模式。
获得你想要的未来 | www.capgemini.com
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For the minority of cases where MRI might assist (i.e., prior negative biopsies), the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates MRI fusion-based targeting. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).